Obsidan (Propranolol Hydrochloride)

Obsidan (propranolol) acts on the cardiovascular system to control heart rate and blood pressure.

• Hypertension: helps lower elevated blood pressure and reduce cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Cardiac arrhythmias: stabilizes abnormal heart rhythms such as supraventricular tachycardia.
• Migraine prophylaxis: reduces frequency and severity of migraine attacks.
• Essential tremor: diminishes tremor amplitude in the hands.
• Portal hypertension: lowers portal venous pressure in patients with cirrhosis.

• Propranolol is a non‑selective beta‑adrenergic antagonist that blocks β1 and β2 receptors in cardiac and smooth‑muscle tissue. By inhibiting catecholamine binding, it reduces heart rate, myocardial contractility, and renin release, leading to decreased cardiac output and lower systemic vascular resistance.

Propranolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fatigue
• Dizziness
• Cold extremities
• Gastrointestinal upset
• Sleep disturbances
• Bradycardia

Serious or Rare Side Effects

• Severe bronchospasm
• Hypotension
• Heart block
• Acute heart failure
• Depression or mood changes
• Allergic skin reactions

When prescribing Obsidan, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate for bradycardia or heart block before initiation.
• Respiratory status: avoid in patients with active asthma or severe COPD.
• Diabetes monitoring: beta‑blockade can mask hypoglycaemia symptoms.
• Thyroid disease: use cautiously in hyperthyroid patients.
• Drug discontinuation: taper gradually to prevent rebound tachycardia.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Propranolol interacts with several medicines that can alter its effectiveness or safety.

Major Interactions (Avoid)

• Calcium channel blockers (e.g., verapamil, diltiazem): increased risk of bradycardia and AV‑block.
• Antidiabetic agents (insulin, sulfonylureas): enhanced hypoglycaemic effect.
• Non‑selective MAO‑inhibitors:

Moderate Interaction ​​      t   t  t t  t"""